MEA and Pakistan offer many advantages for Pharmaceutical and Biotech companies:

• High recruiting countries: wide population, very centralized sites, high motivation from the patients and the PIs to participate to Clinical Trials, as it means easier access to innovative drugs and treatments
• Promising new markets: by the size of their population and their roaring demography, all experts consider that the MEA and Pakistan pharmaceutical market is going to boom in a near future (In Africa, the population is expected to reach 2.5 billions in 2050)
• Rich markets: the Gulf countries and Saudi Arabia represent rich markets, in which many sponsors have decided to invest in line with their growth plans